CHCWM – Cancer & Hematology Centers of West Michigan

XMT-1536-2A (Mersana)

An Open-Label, Multipcenter, Dose Escalation and Expansion Modular, Umbrella Master Study of Upifitamab Rilsodotin In Combination with Other Agents in Participants with High-Grade Serous Ovarian Cancer (Upgrade)